Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.95 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | EYA2 | O00167 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Egtazic Acid SCHEMBL456632 | 1.00 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL456238 | 1.00 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL3042159 | 1.00 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL920203 | 0.98 | BLM (1.00) | BLMPMP22HSD17B10TDP1EYA2 | |
| SCHEMBL11684972 | 0.98 | BLM (1.00) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL22901 | 0.98 | BLM (1.00) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL23859106 | 0.95 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL5067266 | 0.95 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL7541607 | 0.95 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL15413556 | 0.95 | BLM (0.95) | BLMPMP22HSD17B10TDP1EYA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200370120-A1 | REFERENCE MATERIAL FOR NON-INVASIVE PRENATAL TESTING AND MANUFACTURING METHOD THEREOF | BEIJING HOSPITAL (CN) | 2020-11-26 | — | — | US | claimed |
| WO-1992018649-A1 | COMPOSITIONS AND METHODS FOR IMPROVED EXTRACTION AND HYBRIDIZATION OF NUCLEIC ACID | MICROPROBE CORPORATION (US) | 1992-10-29 | — | — | WO | claimed |
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION | 2025-06-05 | — | — | US | disclosed |
| US-12312390-B2 | Rapid-acting insulin analogues of enhanced stability | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025084992-A1 | WOUND DEBRIDEMENT DEVICE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2025-04-24 | — | — | WO | disclosed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | disclosed |
| WO-2023172669-A9 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2024-08-02 | — | — | WO | disclosed |
| CN-113766953-B | N-acyl- {4- [ (4-aryl-phenyl) sulfonylmethyl ] piperidine } compounds and their therapeutic uses | 现代生物科学有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240148679-A1 | METHODS AND COMPOSITIONS RELATED TO TREATMENT AND PREVENTION OF CANCER BY INHIBITION OF DGAT1 AND DGAT2 | OHIO STATE INNOVATION FOUNDATION | 2024-05-09 | — | — | US | disclosed |
| US-20230349921-A1 | Type X Collagen Assays and Methods of Use Thereof | SHRINERS HOSPITALS CHILDREN (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230287525-A1 | METHOD FOR THE CONCENTRATION OF MICROSCOPIC SUBSTANCES DERIVED FROM LIVING ORGANISMS, ENVIRONMENTS, OR FOODS | KTEN BIO INC. (JP) | 2023-09-14 | — | — | US | disclosed |
| WO-1998055615-A9 | APAF-1, THE CED-4 HUMAN HOMOLOG, AN ACTIVATOR OF CASPASE-3 | GENENTECH INC (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998055615-A1 | APAF-1, THE CED-4 HUMAN HOMOLOG, AN ACTIVATOR OF CASPASE-3 | THE UNIVERSITY OF TEXAS BOARD OR REGENTS (US) | 1998-12-10 | — | — | WO | disclosed |
| WO-1998046741-A1 | DNA FRAGMENTATION FACTOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998002579-A9 | REGULATION OF APOPTOSIS AND IN VITRO MODEL FOR STUDIES THEREOF | — | 1998-04-30 | — | — | WO | disclosed |
| WO-1998002579-A1 | REGULATION OF APOPTOSIS AND IN VITRO MODEL FOR STUDIES THEREOF | EMORY UNIVERSITY (US) | 1998-01-22 | — | — | WO | disclosed |
| US-5527690-A | NUCLEIC ACID SEGMENT; ANTICHOLESTEROL AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-06-18 | — | — | US | disclosed |
| US-5498696-A | TO CONTROL HYPERCHOLESTEROLEMIA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-03-12 | — | — | US | disclosed |
| EP-0698115-A1 | METHODS AND COMPOSITIONS RELATING TO STEROL REGULATORY ELEMENT BINDING PROTEINS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-02-28 | — | — | EP | disclosed |
| WO-1994026922-A2 | METHODS AND COMPOSITIONS RELATING TO STEROL REGULATORY ELEMENT BINDING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | ACACB, SREBF2, FASN | BLM 4468/4885PMP22 2575/4885HSD17B10 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.